The FDA has announced the agenda for the July 2026 meeting of the Pharmacy Compounding Advisory Committee (PCAC). The committee will review specific bulk drug substances, including BPC-157 and KPV, for potential inclusion on the 503A Bulks List. This meeting represents a critical regulatory step toward determining the legal status of these peptides for pharmacy compounding.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.